Biochemical and Metabolomic Changes after Electromagnetic Hyperthermia Exposure to Treat Colorectal Cancer Liver Implants in Rats.
animal model
hyperthermia
liver function
liver metastases
metabolomics
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
17 May 2021
17 May 2021
Historique:
received:
14
04
2021
revised:
08
05
2021
accepted:
10
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Hyperthermia (HT) therapy still remains relatively unknown, in terms of both its biological and therapeutic effects. This work aims to analyze the effects of exposure to HT, such as that required in anti-tumor magnetic hyperthermia therapies, using metabolomic and serum parameters routinely analyzed in clinical practice. WAG/RigHsd rats were assigned to the different experimental groups needed to emulate all of the procedures involved in the treatment of liver metastases by HT. Twelve hours or ten days after the electromagnetic HT (606 kHz and 14 kA/m during 21 min), blood samples were retrieved and liver samples were obtained. 1H-nuclear-magnetic-resonance spectroscopy (1H-NMR) was used to search for possible diagnostic biomarkers of HT effects on the rat liver tissue. All of the data obtained from the hydrophilic fraction of the tissues were analyzed and modeled using chemometric tools. Hepatic enzyme levels were significantly increased in animals that underwent hyperthermia after 12 h, but 10 d later they could not be detected anymore. The metabolomic profile (main metabolic differences were found in phosphatidylcholine, taurine, glucose, lactate and pyruvate, among others) also showed that the therapy significantly altered metabolism in the liver within 12 h (with two different patterns); however, those changes reverted to a control-profile pattern after 10 days. Magnetic hyperthermia could be considered as a safe therapy to treat liver metastases, since it does not induce irreversible physiological changes after application.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperthermia (HT) therapy still remains relatively unknown, in terms of both its biological and therapeutic effects. This work aims to analyze the effects of exposure to HT, such as that required in anti-tumor magnetic hyperthermia therapies, using metabolomic and serum parameters routinely analyzed in clinical practice.
METHODS
METHODS
WAG/RigHsd rats were assigned to the different experimental groups needed to emulate all of the procedures involved in the treatment of liver metastases by HT. Twelve hours or ten days after the electromagnetic HT (606 kHz and 14 kA/m during 21 min), blood samples were retrieved and liver samples were obtained. 1H-nuclear-magnetic-resonance spectroscopy (1H-NMR) was used to search for possible diagnostic biomarkers of HT effects on the rat liver tissue. All of the data obtained from the hydrophilic fraction of the tissues were analyzed and modeled using chemometric tools.
RESULTS
RESULTS
Hepatic enzyme levels were significantly increased in animals that underwent hyperthermia after 12 h, but 10 d later they could not be detected anymore. The metabolomic profile (main metabolic differences were found in phosphatidylcholine, taurine, glucose, lactate and pyruvate, among others) also showed that the therapy significantly altered metabolism in the liver within 12 h (with two different patterns); however, those changes reverted to a control-profile pattern after 10 days.
CONCLUSIONS
CONCLUSIONS
Magnetic hyperthermia could be considered as a safe therapy to treat liver metastases, since it does not induce irreversible physiological changes after application.
Identifiants
pubmed: 34067780
pii: nano11051318
doi: 10.3390/nano11051318
pmc: PMC8156717
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Agencia Estatal de Investigación (AEI) and European Regional Development Fund (ERDF)
ID : CTM2017-84763-C3-1-R
Organisme : Basque Government
ID : IT-742-13
Références
Int J Hyperthermia. 2005 Aug;21(5):473-87
pubmed: 16048843
Eur Surg Res. 2020;61(4-5):136-142
pubmed: 33333523
Cancer Res. 2014 Dec 15;74(24):7442-52
pubmed: 25336191
Int J Nanomedicine. 2012;7:2399-410
pubmed: 22661893
Jpn J Surg. 1988 May;18(3):276-83
pubmed: 3404776
Radiologia. 2012 May-Jun;54(3):251-9
pubmed: 21640363
Beilstein J Nanotechnol. 2016 Oct 28;7:1532-1542
pubmed: 28144504
Hepatology. 1995 Jan;21(1):207-14
pubmed: 7806156
Int J Hyperthermia. 2005 Nov;21(7):637-47
pubmed: 16304715
ACS Nano. 2011 Aug 23;5(8):6279-96
pubmed: 21732678
Nanotechnology. 2011 Jul 1;22(26):265102
pubmed: 21576784
Hepatology. 2009 Dec;50(6):1818-26
pubmed: 19824078
Clin Lab Med. 1986 Sep;6(3):491-505
pubmed: 3527542
Nanotechnology. 2015 Jan 9;26(1):015704
pubmed: 25490677
J Proteome Res. 2010 Jan;9(1):59-69
pubmed: 19445528
Ultrasound Med Biol. 2020 Jun;46(6):1504-1512
pubmed: 32178957
Rev Recent Clin Trials. 2009 Jan;4(1):56-62
pubmed: 19149763
J Pediatr. 2017 Mar;182:217-222.e3
pubmed: 28088395
Int J Hyperthermia. 2011;27(5):491-502
pubmed: 21756046
Methods Mol Biol. 2007;358:229-46
pubmed: 17035689
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Int J Hyperthermia. 2003 May-Jun;19(3):373-84
pubmed: 12745976
J Proteome Res. 2011 Jul 1;10(7):3239-45
pubmed: 21568267
Br J Radiol. 2004 Sep;77(921):713-23
pubmed: 15447955
Clin Chem Lab Med. 1998 Nov;36(11):871-8
pubmed: 9877094
Int J Cancer. 2013 Jun 1;132(11):2648-58
pubmed: 23161620
Anal Bioanal Chem. 2015 May;407(12):3405-16
pubmed: 25814271
BMC Biotechnol. 2009 Oct 05;9:84
pubmed: 19804631
IEE Proc Nanobiotechnol. 2005 Feb;152(1):33-9
pubmed: 16441156
Cancer Res. 2006 Sep 15;66(18):8927-30
pubmed: 16982728
J Proteome Res. 2010 May 7;9(5):2527-38
pubmed: 20402505
Biomaterials. 2009 Jan;30(1):52-7
pubmed: 18848723
Clin Chem. 2007 May;53(5):916-21
pubmed: 17384007
Ann Surg. 1957 Oct;146(4):596-606
pubmed: 13470751
Nanoscale. 2014 Jul 7;6(13):7542-52
pubmed: 24890223
Nutr Metab (Lond). 2010 Jan 27;7:7
pubmed: 20181022
J Proteome Res. 2012 Oct 5;11(10):4992-5004
pubmed: 22838963
World J Hepatol. 2019 Feb 27;11(2):150-172
pubmed: 30820266
Arch Intern Med. 1979 Nov;139(11):1229-32
pubmed: 508018
Am J Pathol. 2011 May;178(5):1949-52
pubmed: 21514412
Nat Rev Drug Discov. 2011 Aug 31;10(9):671-84
pubmed: 21878982
Indian J Clin Biochem. 2014 Jul;29(3):269-78
pubmed: 24966474
Nanomaterials (Basel). 2018 Jun 03;8(6):
pubmed: 29865277
Anal Biochem. 2008 Jan 15;372(2):204-12
pubmed: 17963684
Mol Cancer. 2011 Jun 07;10:70
pubmed: 21649891
World J Surg Oncol. 2016 Jan 20;14(1):15
pubmed: 26791262
J Neurooncol. 2007 Jan;81(1):53-60
pubmed: 16773216
Indian J Crit Care Med. 2015 Jan;19(1):27-33
pubmed: 25624647